Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ApTOLL in Healthy Volunteers
NCT04742062Phase 1Completed
- Sponsor
- aptaTargets
- Start
- Jul 2019
- Primary completion
- Feb 2020
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aptoll in ischemic stroke (4 arms), sponsored by aptaTargets. Primary endpoints: Incidence of Adverse Events at Day 15, Peak Plasma Concentration and 1 more. Started Jul 2019; status: completed.
02
Drugs
aptoll
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04742062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742062.